A 15-year veteran of the recruitment industry, Scott Robarge is the founder of Another8, a firm that helps technology companies hire the best talent for their organization. In addition to his work at Another8, Scott Robarge supports the Alzheimer’s Association.
The Alzheimer’s Association works to improve care for patients and advance research. Recently, the organization announced that it will grant $8 million to support the Longitudinal Evaluation of Amyloid Risk and Neurodegeneration (LEARN) study and expand the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4) prevention trial. The grant is the Alzheimer’s Association’s largest to date and will be distributed over the course of four years.
The LEARN study will use an innovative PET scan of the brain to determine the causes of cognitive decline beyond the buildup of amyloid beta. This research will expand scientific knowledge of individual variation of the disease. The A4 study, which also receives funding from the National Institutes of Health, is investigating whether Alzheimer’s disease can be prevented or slowed through treatments that block amyloid beta buildup. The study focuses on individuals who have not experienced memory problems or cognitive difficulties.